30 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
Chee, our President and Chief Executive Officer, Nancy A. Simonian, M.D., our former President and Chief Executive Officer prior to her retirement … and fiscal 2023. In connection with Dr. Simonian’s retirement, we entered into a retirement and transition agreement with Dr. Simonian, pursuant
8-K
EX-1.1
r7fb0vzlprbmqt75 o7
19 Dec 23
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
4:59pm
8-K
sb0cz vd5yko2
2 Oct 23
Cost Associated with Exit or Disposal Activities
8:49am
425
1y86nn43q631
5 Jul 22
Business combination disclosure
7:14am
8-K
EX-2.1
pgmsdu
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
8-K
EX-1.1
iy1v8v0x
20 Jan 21
Syros Announces Proposed Offering of Common Stock
4:04pm